AIMS: We have previously shown that activation of leptin signalling in the heart reduces cardiac morbidity and mortality after myocardial infarction (MI). In the present study, we tested the hypothesis that leptin signalling limits cardiac apoptosis after MI through activation of signal transducer and activator of transcription (STAT)-3 responsive anti-apoptotic genes, including B-cell lymphoma (bcl)-2 and survivin, that serve to downregulate the activity of caspase-3. METHODS AND RESULTS: Hearts from C57BL/6J and three groups of leptin-deficient Ob/Ob mice (food-restricted, ad libitum, and leptin-repleted) were examined 4 weeks after permanent left coronary artery ligation or sham operation. Inflammatory and apoptotic cell number was determined in cardiac sections by immunostaining. Expression of cardiac bcl-2, survivin, and pro and active caspase-3 was determined and correlated with in vitro caspase-3 activity. In the absence of MI, both lean and obese leptin-deficient mice exhibited increased cardiac apoptosis compared with wild-type mice. After MI, the highest rates of apoptosis were seen in the infarcted tissue of lean and obese Ob/Ob mice. Further, leptin-deficient hearts, as well as hearts from wild-type mice treated with the STAT-3 inhibitor WP1066, exhibited blunted anti-apoptotic bcl-2 and survivin gene expression, and increased caspase-3 protein expression and activity. The increased caspase-3 activity and apoptosis in hearts of leptin-deficient mice after MI was significantly attenuated in Ob/Ob mice replete with leptin, reducing apoptosis to levels comparable to that observed in wild-type mice after MI. CONCLUSION: These results demonstrate that intact leptin signalling post-MI acts through STAT-3 to increase anti-apoptotic bcl-2 and survivin gene expression and reduces caspase-3 activity, consistent with a cardioprotective role of leptin in the setting of chronic ischaemic injury.
AIMS: We have previously shown that activation of leptin signalling in the heart reduces cardiac morbidity and mortality after myocardial infarction (MI). In the present study, we tested the hypothesis that leptin signalling limits cardiac apoptosis after MI through activation of signal transducer and activator of transcription (STAT)-3 responsive anti-apoptotic genes, including B-cell lymphoma (bcl)-2 and survivin, that serve to downregulate the activity of caspase-3. METHODS AND RESULTS: Hearts from C57BL/6J and three groups of leptin-deficient Ob/Ob mice (food-restricted, ad libitum, and leptin-repleted) were examined 4 weeks after permanent left coronary artery ligation or sham operation. Inflammatory and apoptotic cell number was determined in cardiac sections by immunostaining. Expression of cardiac bcl-2, survivin, and pro and active caspase-3 was determined and correlated with in vitro caspase-3 activity. In the absence of MI, both lean and obese leptin-deficientmice exhibited increased cardiac apoptosis compared with wild-type mice. After MI, the highest rates of apoptosis were seen in the infarcted tissue of lean and obese Ob/Ob mice. Further, leptin-deficient hearts, as well as hearts from wild-type mice treated with the STAT-3 inhibitor WP1066, exhibited blunted anti-apoptotic bcl-2 and survivin gene expression, and increased caspase-3 protein expression and activity. The increased caspase-3 activity and apoptosis in hearts of leptin-deficientmice after MI was significantly attenuated in Ob/Ob mice replete with leptin, reducing apoptosis to levels comparable to that observed in wild-type mice after MI. CONCLUSION: These results demonstrate that intact leptin signalling post-MI acts through STAT-3 to increase anti-apoptotic bcl-2 and survivin gene expression and reduces caspase-3 activity, consistent with a cardioprotective role of leptin in the setting of chronic ischaemic injury.
Authors: Ling-Yuan Kong; Mohamed K Abou-Ghazal; Jun Wei; Arup Chakraborty; Wei Sun; Wei Qiao; Gregory N Fuller; Izabela Fokt; Elizabeth A Grimm; Robert J Schmittling; Gary E Archer; John H Sampson; Waldemar Priebe; Amy B Heimberger Journal: Clin Cancer Res Date: 2008-09-15 Impact factor: 12.531
Authors: Catherine Communal; Marius Sumandea; Pieter de Tombe; Jagat Narula; R John Solaro; Roger J Hajjar Journal: Proc Natl Acad Sci U S A Date: 2002-04-23 Impact factor: 11.205
Authors: Bodo Levkau; Michael Schäfers; Jeremias Wohlschlaeger; Karin von Wnuck Lipinski; Petra Keul; Sven Hermann; Naomasa Kawaguchi; Paulus Kirchhof; Larissa Fabritz; Jörg Stypmann; Lars Stegger; Ulrich Flögel; Jürgen Schrader; Jens W Fischer; Jens Fischer; Patrick Hsieh; Yen-Ling Ou; Felix Mehrhof; Klaus Tiemann; Alexander Ghanem; Marek Matus; Joachim Neumann; Gerd Heusch; Kurt W Schmid; Edward M Conway; Hideo A Baba Journal: Circulation Date: 2008-03-10 Impact factor: 29.690
Authors: R Faggioni; J Jones-Carson; D A Reed; C A Dinarello; K R Feingold; C Grunfeld; G Fantuzzi Journal: Proc Natl Acad Sci U S A Date: 2000-02-29 Impact factor: 12.779
Authors: Shishir Sharma; Laura A Colangelo; Matthew A Allison; Joao A C Lima; Bharath Ambale-Venkatesh; Satoru Kishi; Kiang Liu; Philip Greenland Journal: Int J Cardiol Date: 2015-05-14 Impact factor: 4.164
Authors: Sarah R Anthony; Adrienne R Guarnieri; Anamarie Gozdiff; Robert N Helsley; Albert Phillip Owens; Michael Tranter Journal: Clin Sci (Lond) Date: 2019-11-29 Impact factor: 6.124
Authors: Carlos M Diaz-Melean; Virend K Somers; Juan Pablo Rodriguez-Escudero; Prachi Singh; Ondrej Sochor; Ernesto Manuel Llano; Francisco Lopez-Jimenez Journal: Curr Atheroscler Rep Date: 2013-11 Impact factor: 5.113